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Introduction: Thyroid transcription factor 1 (TTF1) is a master reg-
ulator of pulmonary differentiation that is downregulated in a subset 
of lung adenocarcinoma, of which the clinicopathologic characteris-
tics were not fully clarified.
Methods: One thousand forty-two lung adenocarcinoma patients 
who underwent surgery were investigated for clinic characteristics, 
histologic subtyping, and spectrum of well-identified driver muta-
tions. TTF1 expression was correlated with these clinicopathologic 
factors and survival.
Results: Compared with TTF1 positive (TTF1+) patients, the 133 
negative individuals (12.8%, TTF1−) were more likely to be male 
(p = 0.006) and heavy smokers (p = 0.002) who had larger tumor size 
(p < 0.001) and more advanced disease stage (p < 0.001). TTF1− pre-
sented more in solid and invasive mucinous-predominant carcinomas 
(both p < 0.001), whereas TTF1+ was identified in 100% patients with 
adenocarcinoma in situ, minimally invasive and lepidic-predominant 
adenocarcinomas. The TTF1− tumors harbored the known driver 
mutations in significantly low frequency compared with TTF1+ 
adenocarcinomas (57.8% versus 78.1%, p < 0.001), especially in 
epidermal growth factor receptor (EGFR) mutations (37.6% versus 
60.7%, p < 0.001). There was no significant difference in recurrence-
free survival between the TTF1− and TTF1+ patients, either for the 
whole cohort or stratified by pathologic stage, or among the driver 
mutation-defined subsets. However, recurrence of multiple metasta-
ses was more likely to occur in patients with TTF1− adenocarcino-
mas (88.1% versus 32.4%, p < 0.001). Multivariate analysis revealed 
that TTF1−  independently predicted both poor postrecurrence sur-
vival (hazard ratio = 1.664; 95% confidence interval , 1.097–2.524; 
p = 0.017) and unfavorable overall survival (hazard ratio = 1.553; 
95% confidence interval , 1.013–2.381; p = 0.043).
Conclusions: TTF1− correlated with solid and invasive mucinous 
subtypes of lung adenocarcinoma and lower frequency of EGFR 
mutations. It defines a subgroup of lung adenocarcinomas with unfa-
vorable outcomes.
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Thyroid transcription factor 1 (TTF1), a homeodomain-containing nuclear transcriptional protein of the Nkx2 gene 
family, is a transcription factor that regulates the expression of 
multiple genes involved in lung development.1 In normal lung, 
TTF1 plays a decisive role in the maintenance of the function of 
terminal respiratory unit cells.2 Positive TTF1 (TTF1+) staining 
by immunohistochemistry (IHC) has been detected in primary 
lung adenocarcinomas and was used as a diagnostic marker.3,4 
TTF1 controls tumor differentiation and limits metastatic poten-
tial in vivo. Upregulation of TTF1 was correlated with favorable 
survival and downregulation linked to loss of differentiation, 
enhanced tumor seeding ability, and increased metastatic pro-
clivity.5 Moreover, a recent investigation using a genetically 
engineering mouse model indicated that lung adenocarcinomas 
with KRAS and TP53 mutations required additional alterations, 
such as loss of TTF1 expression, to initiate the metastatic cas-
cade.6 Also, other major oncogenic mutations in lung adeno-
carcinoma have been found to occur in EGFR, BRAF, HER2, 
ALK, ROS1, and RET. Those gene mutations defined subsets of 
lung cancers that could be amenable to treatment with specific 
kinase inhibitors.1 However, whether the patients with negative 
TTF1 (TTF1−) expression lung adenocarcinoma harbor those 
targetable mutations are still largely unknown.
The International Association for the Study of Lung 
Cancer/American Thoracic Society/European Respiratory 
Society has provided a new classification for lung adenocar-
cinoma, which has been reported to be associated with prog-
nosis.7 Previous studies have been demonstrated that TTF1+ 
expression was associated with lepidic, acinar, papillary, and 
micropapillary predominant adenocarcinoma but did not draw 
a definite conclusion at the association of TTF1− expression 
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with this novel classification system in lung adenocarcinoma 
because of the limited number of cases.8–16
Here, we analyzed 1042 resected pulmonary adenocarci-
nomas for TTF1 expression and described the clinicopathologic 
and mutational characteristics in patients with TTF1− tumors. 
These investigations allowed us to define the specific character-
istics associated with TTF1− lung adenocarcinomas.
PATIENTS AND METHODS
Between 2008 and 2013, consecutive patients with 
pulmonary tumors were prospectively included. After pre-
operative work-up (enhanced thoracic computed tomogra-
phy, abdominal ultrasonography, brain magnetic resonance 
imaging, and bone scan for all patients and positron emis-
sion tomography/computed tomography for some) to exclude 
regional and systemic disease, patients underwent surgery 
with curative intent at Fudan University Shanghai Cancer 
Center. Lymphadenectomy was routinely done for all patients, 
and adjuvant chemotherapy was suggested for those who had 
nodal metastases. Inclusion criteria for this study included 
(1) patients with pulmonary tumors underwent complete 
resection with curative intent; (2) pathologically confirmed 
lung adenocarcinomas and sufficient tissue for comprehensive 
mutational analyses; (3) those with history of adenocarcinomas 
from other organs were excluded from this study. Clinical data 
were collected from the prospectively maintained database. 
Disease stage was based on the 7th edition of the American 
Joint Committee on Cancer staging manual.17 Recurrence-free 
survival (RFS) and overall survival (OS) were recorded based 
on follow-up clinic or telephone. The Institutional Review 
Board of Fudan University Shanghai Cancer Center approved 
this study. All patients gave written informed consent.
Histologic Evaluation and 
Immunohistochemical Analysis of TTF1
IHC was performed on 4-μm thick formalin-fixed, par-
affin-embedded sections. Slides were deparaffinized and pre-
treated with 1 mmol/liter ethylenediaminetetraacetic acid and 
heat-mediated antigen retrieval solution in a microwave oven. 
Further steps were done at room temperature in a hydrated 
chamber. Slides were preincubated in 20% normal goat 
serum. TTF1 (1:100, 8g7g3/1, DAKO, glostrop, Denmark) 
were applied. The slides were then washed in Tris–HCl and 
detected with horseradish peroxidase-conjugated anti-rabbit 
EnVision+ kit (DAKO). All slides were counterstained with 
hematoxylin. Adenocarcinoma was further confirmed using 
IHC method. Solid-predominant tumors were diagnosed based 
on some amount (≥5%) of other histologic patterns (lepidic, 
acinar, papillary, or micropapillary). Two pathologists (L.S. 
and Y.L.) blindly reviewed the slides. We used whole tissue 
blocks to identify TTF1 status. Nuclear staining of tumor cells 
was considered TTF1+. Tumors with completely no TTF1 
expression in nuclei were defined as TTF1−. All tumors were 
classified according to the new classification system.7
Mutational Analysis
EGFR (exons 18–22), HER2 (exons 18–21), KRAS 
(exons 2–3), and BRAF (exons 11–15) were amplified by 
polymerase chain reaction (PCR) using cDNA from each 
tumor specimen. Sanger sequencing was then performed to 
analyze the amplified products. A combination strategy of 
quantitative real-time PCR and reverse transcriptase PCR was 
used to detect ALK, ROS1, and RET fusions, with validation 
using fluorescent in situ hybridization.18–21
Statistical Analysis
Pearson’s χ2 test or Fisher’s exact test was used to 
investigate the associations between the categorical vari-
ables. Comparison of continuous variables was examined by 
independent Student’s t test and Mann‒Whitney U test. The 
survival distribution was analyzed using the Kaplan‒Meier 
method, and log-rank tests were employed for comparisons 
between two categories in univariate analysis. Multivariate 
survival analysis was conducted using the Cox proportional 
hazards regression (forward likelihood ratio model) to identify 
independent prognostic factors. All statistical analyses were 
two-sided, with p value less than or equal to 0.05 indicative 
of statistical significance, and performed using SPSS (version 
19.0 IBM Corporation, Armonk, NY).
RESULTS
Clinicopathologic Data and 
Correlation With TTF1 Expression
A total of 1042 consecutive patients with lung adeno-
carcinoma were included in this study, of which 133 (12.8%) 
cases with completely negative TTF1 expression in nuclei. 
Clinicopathologic parameters analyzed included age, sex, 
smoking history, tumor size, lymph nodal status, and patho-
logic stage. Compared with TTF1+ adenocarcinoma, negative 
patients are more likely to be male (p = 0.006) and heavy smok-
ers (p = 0.002). They also had larger tumor size (p < 0.001) 
and more advanced disease stage (p < 0.001). In addition, 
TTF1 expression was not significantly associated with age 
(p = 0.219) and lymph node metastasis (p = 0.753; Table 1).
Association Between TTF1 and 
Histologic Subtypes
Among TTF1− group, the major subtype was acinar-pre-
dominant adenocarcinomas (36.8%), followed by solid (32.3%) 
and invasive-mucinous (18.1%) subtypes. Of the TTF1+ 
tumors, acinar (48.6%), solid (13.1%), and papillary (12.5%) 
were in the majority. There were no adenocarcinoma in situ, 
minimally invasive adenocarcinomas, or lepidic-predominant 
tumors in TTF1− group. However, compared with the TTF1+ 
adenocarcinomas, TTF1− tumors presented more as solid and 
invasive mucinous subtypes (both p < 0.001), whereas less in 
acinar component (p = 0.007). Among the 86 invasive-mucinous 
tumors, there were 18 (20.9%) cases with pure-mucinous com-
ponent, which were all negative for the TTF1 staining. In addi-
tion, the two enteric cases showed no TTF1 staining (Table 1).
Status of Common Oncogenic Mutations
The prevalence of the driver mutations was similar as 
previously reported for the study population.2,19–21 Compared 
with TTF1+ tumors, TTF1− adenocarcinomas harbored 
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significantly lower frequency of EGFR mutations (37.6% 
versus 60.7%, p < 0.001) while inclined to have more BRAF 
mutation (3% versus 1%, p = 0.076). TTF1− adenocarcinomas 
were more likely to be “pan-negative” for the common driver 
mutations (42.1% versus 22.0%, p < 0.001; Table 1).
Survival Analysis
Survival outcomes were compared between 119 TTF1-
negative patients and 332 TTF1+ patients who had been 
followed up for over 12 months since surgery. The baseline 
characteristics of the two groups were well balanced with each 
other (Table 2).
On univariate analysis, although the two groups seemed to 
share similar RFS (p = 0.416, Fig. 1A), the patients with TTF1− 
tumors had a worse OS than the positive cases (5-year OS: 42.8% 
versus 72.8%, p = 0.001, Fig. 1B). When the survival analysis 
was limited to stage I patients, the survival difference between 
the two groups was significant regarding OS (p = 0.002) but not 
for RFS (p = 0.556; Fig. 1C and D). When confined into each 
driver mutation-defined subsets, there was no OS difference 
between TTF1− and TTF1+ groups for EGFR or KRAS-mutated 
tumors (p = 0.157 and p = 0.699, respectively). However, for 
those with “pan-negative” mutations, TTF1− patients presented 
inferior OS compared with TTF1+ ones (5-year OS: 46.4% ver-
sus 77.9%, p = 0.041, Fig. 1E and F).
On multivariate survival analysis adjusting for gender, 
age, smoking history, histologic subtype, pathologic stage, 
lymphovascular invasion, and EGFR mutational status, TTF1− 
proved to be an independent predictor of poor OS for patients 
with adenocarcinoma (hazard ratio = 1.553; 95% confidence 
interval , 1.013‒2.318; p = 0.043; Table 3).
A total of 59 (49.6%) TTF1− and 171 (51.5%) TTF1+ 
patients experienced disease recurrence. When comparing 
pattern of recurrence, we found that the recurrence of mul-
tiple metastases was more likely to occur in patients with 
TTF1− adenocarcinomas (88.1% versus 32.4%, p < 0.001). 
As to postrecurrence survival (PRS), TTF1− patients had sig-
nificantly worse PRS than TTF1+ adenocarcinoma patients 
on univariate analysis (p = 0.001, Fig. 2). Pathologic stage, 
TTF1 status, and EgFR-tyrosine kinase inhibitor treatment 
after recurrence were independent predictors of PRS as dem-
onstrated on multivariate analysis (Table 4). In addition, there 
seemed no difference in OS (p = 0.749) or PRS (p = 0.505) 
categorized by different TTF1 status for those who have 
received EgFR-tyrosine kinase inhibitor therapy (Fig. 3).
DISCUSSION
TTF1, a homeodomain transcription factor also 
known as NKX2-1, is a reliable lineage marker for terminal 
TABLE 1.  Clinicopathologic Factors of the Whole Cohort
Variable
TTF1−  
(n = 133)
TTF1+  
(n = 909) P
gender (female/male) 57/76 506/403 0.006
Age (mean ± SD, yr) 60.1 ± 10.9 59.6 ± 9.9 0.219
Smoking history 61 (45.9%) 287 (31.6%) 0.002
Tumor size (mean ± SD, cm) 3.60 ± 2.13 2.63 ± 1.47 <0.001
N status 0.753
  N0 81 (60.9%) 581 (63.9%)
  N1 15 (11.3%) 102 (11.2%)
  N2 37 (27.8%) 226 (24.9%)
Pathologic stage <0.001
  0 0 15 (1.7%)
  I 58 (43.6%) 520 (57.2%)
  II 34 (25.6%) 101 (11.1%)
  III 41 (30.8%) 273 (30.0%)
Subtypes
  AIS 0 19 (2.1%) <0.001
  MIA 0 29 (3.2%) <0.001
  Lepidic 0 105 (11.6%) <0.001
  Acinar 49 (36.8%) 442 (48.6%) 0.007
  Papillary 14 (10.5%) 114 (12.5%) 0.468
  Micropapillary 1 (0.8%) 19 (2.1%) 0.499
  Solid 43 (32.3%) 119 (13.1%) <0.001
  Invasive mucinous 24 (18.1%) 62 (6.8%) <0.001
  Enteric 2 (1.5%) 0 <0.001
Mutational status
  EGFR mutation 50 (37.6%) 552 (60.7%) <0.001
  KRAS mutation 13 (9.7%) 67 (7.4%) 0.363
  HER2 mutation 2 (1.5%) 25 (2.8%) 0.564
  BRAF mutation 4 (3.0%) 9 (1.0%) 0.076
  ALK fusion 5 (3.8%) 37 (4.0%) 0.836
  ROS1 fusion 2 (1.5%) 7 (0.8%) 0.329
  RET fusion 1 (0.8%) 12 (1.3%) 1.000
  Pan-negative 56 (42.1%) 200 (22.0%) <0.001
TTF, thyroid transcription factor; AIS, adenocarcinoma in situ; MIA, minimally 
invasive adenocarcinomas.
TABLE 2.  Baseline Characteristics of the Patients Included 
for Survival Analysis
Variable
TTF1−  
(n = 119)
TTF1+  
(n = 332) P
gender (female/male) 57/62 177/155 0.310
Age (mean ± SD, yr) 60.3 ± 11.2 58.4 ± 10.0 0.172
Surgery 1.00
  Lobectomy 117 (98.3%) 325 (97.9%)
  Sublobar resection 2 (1.7%) 7 (2.1%)
Pathologic stage 0.132
  IA 30 (25.3%) 108 (32.5%)
  IB 23 (19.3%) 51 (15.4%)
  II 28 (23.5%) 53 (16.0%)
  III 38 (31.9%) 120 (36.1%)
Lymphovascular invasion 0.279
  Present 32 (26.9%) 107 (30.8%)
  Absent 87 (73.1%) 225 (69.2%)
Adjuvant chemotherapy 0.686
  Yes 67 (56.3%) 194 (58.4%)
  No 52 (43.7%) 138 (41.6%)
TTF1, thyroid transcription factor 1.
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respiratory unit cells. Mouse model researches revealed that 
downregulation of TTF1 would link to loss of differentiation, 
enhanced tumor seeding ability, and increased metastatic pro-
clivity in lung adenocarcinomas.5,6 In this study, we reviewed 
a large sample of completely resected lung adenocarcinomas 
to have a comprehensive assessment of the clinicopathologic 
characteristics, mutational status, patterns of recurrence, and 
survival associated with TTF1− adenocarcinoma. The results 
demonstrate that a lack of TTF1 expression is identified more 
frequently in male smokers with large tumors that present 
advanced disease stage. Once relapsed, patients with TTF1− 
adenocarcinomas inclined to experience multiple metastases. 
These data validate the conclusion of the basic studies from a 
clinical point of view.
FIGURE 1.  Kaplan–Meier survival 
curves for recurrence-free sur-
vival (RFS)and overall survival 
(OS) according to TTF1 status. 
A, RFS in all patients; B, OS in 
all patients; C, RFS in pathologic 
stage I patients; D, OS in patho-
logic stage I patients; E, RFS in the 
patients with tumors of “pan-
negative” mutation; F, OS in the 
patients with tumors of “pan-
negative” mutation.
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In 2011, a new lung adenocarcinoma classification sys-
tem was proposed by the International Association for the 
Study of Lung Cancer/American Thoracic Society/European 
Respiratory Society.7 In this study, TTF1− adenocarcinomas 
mostly present as acinar, solid, and invasive-mucinous sub-
types but none as minimally invasive adenocarcinomas or 
lepidic component, which is in consistence with the previous 
report.15 Moreover, all pure mucinous adenocarcinomas were 
negative for TTF1 staining, indicating that TTF1 insufficiency 
may induce mucinous adenocarcinoma of the lung.22
Molecularly, lung adenocarcinoma can be classified 
into oncogenic driver mutation-defined subsets,2,19–21 each 
with potentials for targeted therapies. Our data indicated 
that TTF1− adenocarcinomas are negatively associated with 
EGFR mutations, which is in accordance with previous 
TABLE 3.  Independent Predictors of Overall Survival
HR 95% CI P
Univariate analysis
  gender, male vs. female 1.868 1.265–2.760 0.002
  Age 0.887 0.980–1.018 0.887
  Smoke, never vs. ever 0.003 1.210–2.598 0.003
  Subtypes
   AIS/MIA/Lepidic — — <0.001
   Acinar 7.064 0.971–51.41 0.054
   Papillary 10.31 1.376–77.28 0.023
   Micropapillary 14.09 1.274–155.7 0.031
   Solid 18.41 2.529–134.0 0.004
   Invasive mucinous 3.856 0.400–37.14 0.243
   Enteric 13.18 0.824–210.8 0.068
  Pathologic stage, I vs. II/III 0.234 0.147–0.372 <0.001
  Lymphovascular invasion,  
absent vs. present
0.368 0.251–0.539 <0.001
  EGFR mutation, no vs. yes 1.784 1.217–2.614 0.003
  TTF1, negative vs. positive 1.991 1.332–2.975 0.001
Multivariate analysis
  gender, male vs. female 1.477 0.859–2.540 0.158
  Smoke, never vs. ever 1.105 0.653–1.871 0.710
  Subtypes
   AIS/MIA/Lepidic — — 0.099
   Acinar 3.745 0.506–27.725 0.196
   Papillary 4.960 0.650–37.85 0.123
   Micropapillary 5.087 0.449–57.69 0.189
   Solid 6.592 0.874–49.73 0.067
   Invasive mucinous 2.148 0.217–21.28 0.513
   Enteric 11.34 0.658–195.5 0.095
  Pathologic stage, I vs. II/III 0.323 0.191–0.549 <0.001
  Lymphovascular invasion,  
absent vs. present
0.668 0.434–1.028 0.067
  EGFR mutation, no vs. yes 1.233 0.802–1.895 0.339
  TTF1, negative vs. positive 1.553 1.013–2.381 0.043
EgFR TKI, epidermal growth factor receptor tyrosine kinase inhibitor; TTF1, 
thyroid transcription factor 1; AIS, adenocarcinoma in situ; MIA, minimally invasive 
adenocarcinomas; CI, confidence interval; HR, hazard ratio.
FIGURE 2.  Kaplan–Meier survival curve for postrecurrence 
survival.
TABLE 4.  Independent Predictors of Postrecurrence Survival
HR 95% CI P
Univariate analysis
  gender, male vs. female 1.425 0.964–2.109 0.076
  Age 1.009 0.990–1.029 0.348
  Smoke, never vs. ever 0.815 0.555–1.196 0.296
  Subtypes
   Lepidic — — 0.080
   Acinar 2.883 0.395–21.02 0.296
   Papillary 3.674 0.490–27.56 0.206
   Micro-papillary 2.470 0.223–27.35 0.461
   Solid 5.046 0.693–36.76 0.110
   Invasive mucinous 1.793 0.186–17.25 0.613
  Pathologic stage, I vs. II/III 0.620 0.390–0.985 0.043
  Lymphovascular invasion, absent 
vs. present
0.830 0.566–1.218 0.342
  EGFR mutation, absent vs. present 1.517 1.034–2.225 0.033
  TTF1, negative vs. positive 2.026 1.356–3.025 0.001
  Adjuvant chemotherapy, no vs. yes 1.197 0.748–1.917 0.454
  Adjuvant radiotherapy, no vs. yes 1.300 0.852–1.982 0.224
  EgFR TKIs, no vs. yes 1.840 1.155–2.931 0.010
Multivariate analysis
  Pathologic stage, I vs. II/III 0.536 0.332–0.865 0.011
  EGFR mutation, absent vs. present 1.244 0.832–1.861 0.287
  TTF1, negative vs. positive 1.664 1.097–2.524 0.017
  EgFR TKIs, no vs. yes 1.887 1.151–3.093 0.012
EgFR TKI, epidermal growth factor receptor tyrosine kinase inhibitor;TTF1, 
thyroid transcription factor 1; CI, confidence interval.
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studies.16,23 Although they have a higher proportion of BRAF 
mutation (3%), 42.2% of this group could not be defined by 
any of the seven common driver mutations, about twice the 
ratio of TTF1+ adenocarcinoma. More attention should be 
paid to this aggressive lung adenocarcinoma subtype to iden-
tify new molecular targets.
The association of TTF1 and survival in lung cancer 
patients has been investigated in numerous studies, most of 
which have reported the poor prognostic role of negative 
TTF1 expression in lung adenocarcinoma.9–15,24–29 Here, we 
further revealed that this subset was an independent poor 
prognostic marker for OS validated by multivariate survival 
analysis incorporating clinicopathologic variables and sta-
tus of well-identified driver mutations. However, when con-
fined into the common oncogenic mutated tumors, there was 
no OS difference between the TTF1− and TTF1+ groups 
(EGFR, p = 0.157 and KRAS p = 0.699). Contrarily, for 
those with “pan-negative” mutations, TTF1− patients pre-
sented inferior OS compared with TTF1+ ones (p = 0.041), 
implying the molecular mechanism for the poor prognosis 
of TTF1− adenocarcinomas may be associated with some 
unknown underpinnings but not with these driver muta-
tions. In addition, we found that the recurrence of multiple 
metastases was more likely to occur in patients with TTF1− 
adenocarcinomas (p < 0.001). This aggressive pattern of 
recurrence provides clinical evidence for the findings in 
the mouse model research6 and may explain the reason why 
TTF1− adenocarcinoma patients shared similar RFS but 
ended in much poor OS.
TTF1− defines a subgroup of lung adenocarcinomas 
with unfavorable outcomes, which may because of the aggres-
sive pattern of recurrence. Future studies are warranted to 
investigate molecular mechanisms of the poor prognosis and 
identify novel therapeutic targets to benefit more patients with 
this aggressive disease.
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